论文部分内容阅读
目的 探讨替尼泊甙（VM26）与司莫司汀（MeCCNU）序列给药治疗恶性脑胶质瘤的疗效及其并发症的防治。方法 对145例经病理证实的恶性胶质瘤病人术后采用超选择性动脉内灌注加静脉滴注VM26及口服MeCCNU化疗，通过比较化疗前后影像学表现评价近期疗效。结果 本组145例病人治疗后完全缓解21例（14.5%）、部分缓解72例（49.6%）、无变化31例（21.4%）、恶化21例（14.5%）。1、2、3年存活率分别为90.3%、74.5%和22.8%。全部病人无严重并发症及毒性反应。结论 VM26-MeCCNU联合序列给药可延长脑胶质瘤病人生存时间，并发症及毒副作用少。
Objective To investigate the curative effect and prevention and treatment of malignant glioma with administration of tenimoside (VM26) and sestamustine (MeCCNU). Methods One hundred and forty-five patients with pathologically confirmed glioblastoma were treated with super selective intra-arterial infusion plus intravenous infusion of VM26 and oral MeCCNU chemotherapy. The short-term effect was evaluated by comparing the imaging findings before and after chemotherapy. Results In this group of 145 patients, complete remission was achieved in 21 cases (14.5%), partial remission in 72 cases (49.6%), no change in 31 cases (21.4%) and deterioration in 21 cases (14.5%). The survival rates at 1, 2 and 3 years were 90.3%, 74.5% and 22.8% respectively. All patients without serious complications and toxicity. Conclusion Combined administration of VM26-MeCCNU can prolong the survival time of glioma patients with fewer complications and side effects.